What is the level of liabilities of Immuron this year?
Immuron has a debt balance of 2.37 M AUD this year.
Immuron Liabilities 2024
Immuron Liabilities
2.37 M AUD
Ticker
IMC.AX
ISIN
AU000000IMC7
WKN
A0RDPK
In 2024, Immuron's total liabilities amounted to 2.37 M AUD, a 41.28% difference from the 1.68 M AUD total liabilities in the previous year.
Immuron Aktienanalyse
What does Immuron do?
Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future. Immuron ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Immuron's Liabilities
Immuron's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Immuron's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Immuron's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Immuron's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Immuron’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Immuron stock
What were the liabilities of Immuron compared to the previous year?
The liabilities of Immuron have increased by 41.28% increased compared to the previous year.
What are the consequences of high debt for investors of Immuron?
High liabilities can pose a risk for investors of Immuron, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Immuron?
Low liabilities mean that Immuron has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Immuron affect the company?
An increase in liabilities of Immuron can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Immuron affect the company?
A decrease in the liabilities of Immuron can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Immuron?
Some factors that can influence the liabilities of Immuron include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Immuron so important for investors?
The liabilities of Immuron are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Immuron take to modify the liabilities?
To change its liabilities, Immuron can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Immuron pay?
Over the past 12 months, Immuron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immuron is expected to pay a dividend of 0 AUD.
What is the dividend yield of Immuron?
The current dividend yield of Immuron is .
When does Immuron pay dividends?
Immuron pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immuron?
Immuron paid dividends every year for the past 0 years.
What is the dividend of Immuron?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immuron located?
Immuron is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immuron kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immuron from 9/12/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did Immuron pay the last dividend?
The last dividend was paid out on 9/12/2024.
What was the dividend of Immuron in the year 2023?
In the year 2023, Immuron distributed 0 AUD as dividends.
In which currency does Immuron pay out the dividend?
The dividends of Immuron are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immuron
Our stock analysis for Immuron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
